My focus is on the pathology and natural history of prostate, testicular and penile cancer working to translate basic research into practical treatments for patients with novel tests and bespoke predictive treatments.
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
My main research interests are in genital and urinary cancers, leading a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.
My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, and liquid biopsy-derived molecular biomarkers of treatment outcomes.
My research focuses on measuring circulating tumour cells as a blood-based biomarker for aggressive prostate cancer.
The aim of my work is to develop clinically-relevant biomarkers that could aid in earlier disease detection, predict treatment response, and inform clinical management of patients.